Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-12

AUTHORS

Anne Gardin, Cathy Gray, Srikanth Neelakantham, Felix Huth, Antonia M. Davidson, Swati Dumitras, Eric Legangneux, Kasra Shakeri-Nejad

ABSTRACT

PURPOSE: To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects. METHODS: This was a confirmatory, open-label, multiple-dose two-period study in healthy subjects (aged 18-45 years). In Period 1 (Days 1-12), siponimod was up-titrated from 0.25 to 2 mg over 5 days (Days 1-6) followed by 2 mg once daily on days 7-12. In Period 2, siponimod 2 mg qd was co-administered with rifampin 600 mg qd (Days 13-24). Primary assessments included PK of siponimod (Days 12 and 24; maximum steady-state plasma concentration [Cmax,ss], median time to achieve Cmax,ss [Tmax, ss], and area under the curve at steady state [AUCtau,ss]). Key secondary assessments were PK of M3 and M5 metabolites, and safety/tolerability including absolute lymphocyte count (ALC). RESULTS: Of the 16 subjects enrolled (age, mean ± standard deviation [SD] 31 ± 8.3 years; men, n = 15), 15 completed the study. In Period 1, siponimod geometric mean Cmax,ss (28.6 ng/mL) was achieved in 4 h (median Tmax,ss; range, 1.58-8.00) and the geometric mean AUCtau,ss was 546 h × ng/mL. In Period 2, the siponimod geometric mean Cmax,ss and AUCtau,ss decreased to 15.7 ng/mL and 235 h × ng/mL, respectively; median Tmax remained unchanged (4 h). Rifampin co-administration increased M3 Cmax,ss by 53% while M5 Cmax,ss remained unchanged. The AUCtau,ss of M3 and M5 decreased by 10% and 37%, respectively. The majority of adverse events reported were mild, with a higher frequency during Period 2 (86.7%) versus Period 1 (50%). The mean ALC increased slightly under rifampin co-administration but remained below 1.0 × 109/L. CONCLUSIONS: The study findings suggest that in the presence of rifampin, a strong CYP3A4/moderate CYP2C9 inducer, siponimod showed significant decrease in Cmax,ss (45%) and AUCtau,ss (57%) in healthy subjects. More... »

PAGES

1593-1604

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00228-018-2533-2

DOI

http://dx.doi.org/10.1007/s00228-018-2533-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106131219

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30105453


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azetidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biotransformation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytochrome P-450 CYP2C9", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Healthy Volunteers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Lysosphingolipid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rifampin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gardin", 
        "givenName": "Anne", 
        "id": "sg:person.0746041340.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746041340.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gray", 
        "givenName": "Cathy", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Pvt. Ltd., Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neelakantham", 
        "givenName": "Srikanth", 
        "id": "sg:person.01254000765.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254000765.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huth", 
        "givenName": "Felix", 
        "id": "sg:person.0601142577.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601142577.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmaceutical Product Development (United States)", 
          "id": "https://www.grid.ac/institutes/grid.423257.5", 
          "name": [
            "PPD, Austin, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davidson", 
        "givenName": "Antonia M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dumitras", 
        "givenName": "Swati", 
        "id": "sg:person.0716366542.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716366542.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Legangneux", 
        "givenName": "Eric", 
        "id": "sg:person.01152111734.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152111734.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shakeri-Nejad", 
        "givenName": "Kasra", 
        "id": "sg:person.01367544315.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367544315.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2012.04400.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002553097"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2012.04400.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002553097"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/j.clpt.2006.08.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007524447", 
          "https://doi.org/10.1016/j.clpt.2006.08.002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.1014154108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013336301"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200342090-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014227941", 
          "https://doi.org/10.2165/00003088-200342090-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200342090-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014227941", 
          "https://doi.org/10.2165/00003088-200342090-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200342090-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014227941", 
          "https://doi.org/10.2165/00003088-200342090-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-9440(10)64794-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017653173"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/pgs.10.49", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020935714"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/ker018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022970028"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12248-012-9367-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031115047", 
          "https://doi.org/10.1208/s12248-012-9367-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(13)70102-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033439649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(13)70102-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033439649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/j.clpt.2004.08.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033907987", 
          "https://doi.org/10.1016/j.clpt.2004.08.009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/157015910792246218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034815003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.109.027565", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035576216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/brain/awq118", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041480930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12974-016-0686-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042047657", 
          "https://doi.org/10.1186/s12974-016-0686-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12974-016-0686-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042047657", 
          "https://doi.org/10.1186/s12974-016-0686-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12974-016-0686-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042047657", 
          "https://doi.org/10.1186/s12974-016-0686-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.2012.02061.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043127544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.2012.02061.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043127544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1471-4159.2007.04629.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045180467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.106.010033", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047422604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pharmthera.2007.04.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050875697"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1471-4159.2007.4629.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1061939563"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202369", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834516"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202369", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834516"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202608", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202608", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-017-2404-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099922651", 
          "https://doi.org/10.1007/s00228-017-2404-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-017-2404-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099922651", 
          "https://doi.org/10.1007/s00228-017-2404-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)30475-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101698897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)30475-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101698897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.117.079574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103850020"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.117.079574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103850020"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0700-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106022094", 
          "https://doi.org/10.1007/s40262-018-0700-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0700-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106022094", 
          "https://doi.org/10.1007/s40262-018-0700-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0700-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106022094", 
          "https://doi.org/10.1007/s40262-018-0700-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0700-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106022094", 
          "https://doi.org/10.1007/s40262-018-0700-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "PURPOSE: To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects.\nMETHODS: This was a confirmatory, open-label, multiple-dose two-period study in healthy subjects (aged 18-45\u00a0years). In Period 1 (Days 1-12), siponimod was up-titrated from 0.25 to 2\u00a0mg over 5\u00a0days (Days 1-6) followed by 2\u00a0mg once daily on days 7-12. In Period 2, siponimod 2\u00a0mg qd was co-administered with rifampin 600\u00a0mg qd (Days 13-24). Primary assessments included PK of siponimod (Days 12 and 24; maximum steady-state plasma concentration [Cmax,ss], median time to achieve Cmax,ss [Tmax, ss], and area under the curve at steady state [AUCtau,ss]). Key secondary assessments were PK of M3 and M5 metabolites, and safety/tolerability including absolute lymphocyte count (ALC).\nRESULTS: Of the 16 subjects enrolled (age, mean \u00b1 standard deviation [SD] 31\u2009\u00b1\u20098.3\u00a0years; men, n\u2009=\u200915), 15 completed the study. In Period 1, siponimod geometric mean Cmax,ss (28.6\u00a0ng/mL) was achieved in 4\u00a0h (median Tmax,ss; range, 1.58-8.00) and the geometric mean AUCtau,ss was 546\u00a0h\u2009\u00d7\u2009ng/mL. In Period 2, the siponimod geometric mean Cmax,ss and AUCtau,ss decreased to 15.7\u00a0ng/mL and 235\u00a0h\u2009\u00d7\u2009ng/mL, respectively; median Tmax remained unchanged (4\u00a0h). Rifampin co-administration increased M3 Cmax,ss by 53% while M5 Cmax,ss remained unchanged. The AUCtau,ss of M3 and M5 decreased by 10% and 37%, respectively. The majority of adverse events reported were mild, with a higher frequency during Period 2 (86.7%) versus Period 1 (50%). The mean ALC increased slightly under rifampin co-administration but remained below 1.0\u2009\u00d7\u2009109/L.\nCONCLUSIONS: The study findings suggest that in the presence of rifampin, a strong CYP3A4/moderate CYP2C9 inducer, siponimod showed significant decrease in Cmax,ss (45%) and AUCtau,ss (57%) in healthy subjects.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00228-018-2533-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "74"
      }
    ], 
    "name": "Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects", 
    "pagination": "1593-1604", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "407e2069a61a2f88a7fd2c7ae7441fb5601a5f500ea2bbbb43f66f98feb06e3b"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30105453"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "1256165"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00228-018-2533-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106131219"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00228-018-2533-2", 
      "https://app.dimensions.ai/details/publication/pub.1106131219"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78950_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00228-018-2533-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2533-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2533-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2533-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2533-2'


 

This table displays all metadata directly associated to this object as RDF triples.

278 TRIPLES      21 PREDICATES      72 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00228-018-2533-2 schema:about N3a020661eeae4bd8b318f227e7bd3d2a
2 N3bdad0a21cea42e28eb076e3b6c6b105
3 N43d6ec08a55a4cb8be7ad74d4dfcc672
4 N61e0179f02b24062a34b6466bc0826ed
5 N6460986bf4a2476b886e48b54956909b
6 N6a1f63630c01475394e0feafbbb62ef9
7 N76f7179fd5fb4b2bb26fe6aafa1d46de
8 N7a91b8f5176d4d459ed1648555e6dcfd
9 N7ec380c3e725456caa309e1d7a679b67
10 N882fcd338a9d4b35b899b43e192e9cd8
11 N9d81ba9e77ec4328847c82f404a029b9
12 Na36e894bbc5f44458c3304563dfe0c28
13 Nb4fe799a8c814d89867512d5c6c8ca86
14 Nccf2a36f918847198b5beb4a6c21c256
15 Nd3fadd97df74497abaf67c461351cba4
16 Ne01edeae6cac48ffa5b52f367e2423da
17 Nf5ab77fdd6024a61a3f790cb443e439d
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N58fca7773c35404a86a11d45a956ef9f
21 schema:citation sg:pub.10.1007/s00228-017-2404-2
22 sg:pub.10.1007/s40262-018-0700-3
23 sg:pub.10.1016/j.clpt.2004.08.009
24 sg:pub.10.1016/j.clpt.2006.08.002
25 sg:pub.10.1186/s12974-016-0686-4
26 sg:pub.10.1208/s12248-012-9367-0
27 sg:pub.10.2165/00003088-200342090-00003
28 https://doi.org/10.1016/j.pharmthera.2007.04.006
29 https://doi.org/10.1016/s0002-9440(10)64794-3
30 https://doi.org/10.1016/s0140-6736(18)30475-6
31 https://doi.org/10.1016/s1474-4422(13)70102-9
32 https://doi.org/10.1073/pnas.1014154108
33 https://doi.org/10.1093/brain/awq118
34 https://doi.org/10.1093/rheumatology/ker018
35 https://doi.org/10.1111/j.1365-2125.2012.04400.x
36 https://doi.org/10.1111/j.1471-4159.2007.04629.x
37 https://doi.org/10.1111/j.1471-4159.2007.4629.x
38 https://doi.org/10.1111/j.1476-5381.2012.02061.x
39 https://doi.org/10.1124/dmd.106.010033
40 https://doi.org/10.1124/dmd.109.027565
41 https://doi.org/10.1124/dmd.117.079574
42 https://doi.org/10.2174/157015910792246218
43 https://doi.org/10.2217/pgs.10.49
44 https://doi.org/10.5414/cp202369
45 https://doi.org/10.5414/cp202588
46 https://doi.org/10.5414/cp202608
47 schema:datePublished 2018-12
48 schema:datePublishedReg 2018-12-01
49 schema:description PURPOSE: To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects. METHODS: This was a confirmatory, open-label, multiple-dose two-period study in healthy subjects (aged 18-45 years). In Period 1 (Days 1-12), siponimod was up-titrated from 0.25 to 2 mg over 5 days (Days 1-6) followed by 2 mg once daily on days 7-12. In Period 2, siponimod 2 mg qd was co-administered with rifampin 600 mg qd (Days 13-24). Primary assessments included PK of siponimod (Days 12 and 24; maximum steady-state plasma concentration [Cmax,ss], median time to achieve Cmax,ss [Tmax, ss], and area under the curve at steady state [AUCtau,ss]). Key secondary assessments were PK of M3 and M5 metabolites, and safety/tolerability including absolute lymphocyte count (ALC). RESULTS: Of the 16 subjects enrolled (age, mean ± standard deviation [SD] 31 ± 8.3 years; men, n = 15), 15 completed the study. In Period 1, siponimod geometric mean Cmax,ss (28.6 ng/mL) was achieved in 4 h (median Tmax,ss; range, 1.58-8.00) and the geometric mean AUCtau,ss was 546 h × ng/mL. In Period 2, the siponimod geometric mean Cmax,ss and AUCtau,ss decreased to 15.7 ng/mL and 235 h × ng/mL, respectively; median Tmax remained unchanged (4 h). Rifampin co-administration increased M3 Cmax,ss by 53% while M5 Cmax,ss remained unchanged. The AUCtau,ss of M3 and M5 decreased by 10% and 37%, respectively. The majority of adverse events reported were mild, with a higher frequency during Period 2 (86.7%) versus Period 1 (50%). The mean ALC increased slightly under rifampin co-administration but remained below 1.0 × 109/L. CONCLUSIONS: The study findings suggest that in the presence of rifampin, a strong CYP3A4/moderate CYP2C9 inducer, siponimod showed significant decrease in Cmax,ss (45%) and AUCtau,ss (57%) in healthy subjects.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree false
53 schema:isPartOf N0fa65232377d445eb3f94b46a3a0b29b
54 N9f62cca8ef33450686a3b58fea9e333a
55 sg:journal.1054337
56 schema:name Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects
57 schema:pagination 1593-1604
58 schema:productId N124f50b7d6ba456180006a919d8cfcca
59 N1c797c76802a4c7b801dfdf2ef702eff
60 N419717ba90bb430fbce080cdafd87b4d
61 Na0185dbcc0244a4f93e4812684d8b51b
62 Nbb843ebfe0db4327a2ae9c49b770ac84
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106131219
64 https://doi.org/10.1007/s00228-018-2533-2
65 schema:sdDatePublished 2019-04-11T13:19
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher N5ae1bdcec5eb46aa924a060368519ae8
68 schema:url https://link.springer.com/10.1007%2Fs00228-018-2533-2
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N0fa65232377d445eb3f94b46a3a0b29b schema:volumeNumber 74
73 rdf:type schema:PublicationVolume
74 N124f50b7d6ba456180006a919d8cfcca schema:name pubmed_id
75 schema:value 30105453
76 rdf:type schema:PropertyValue
77 N1c797c76802a4c7b801dfdf2ef702eff schema:name dimensions_id
78 schema:value pub.1106131219
79 rdf:type schema:PropertyValue
80 N2179b1520d94496e98fa5b0cd70e2942 rdf:first sg:person.01254000765.20
81 rdf:rest N7ebd9338216a480eb78422848da17a6a
82 N3a020661eeae4bd8b318f227e7bd3d2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Rifampin
84 rdf:type schema:DefinedTerm
85 N3bdad0a21cea42e28eb076e3b6c6b105 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Receptors, Lysosphingolipid
87 rdf:type schema:DefinedTerm
88 N3e6c3ee1a422419880b3cae2d2d3767c rdf:first Nd9bb33762ef24b97a38122343e410229
89 rdf:rest N2179b1520d94496e98fa5b0cd70e2942
90 N419717ba90bb430fbce080cdafd87b4d schema:name nlm_unique_id
91 schema:value 1256165
92 rdf:type schema:PropertyValue
93 N43d6ec08a55a4cb8be7ad74d4dfcc672 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Male
95 rdf:type schema:DefinedTerm
96 N4f23939b8e934c2ab4306a7c5a02b1fd schema:affiliation https://www.grid.ac/institutes/grid.423257.5
97 schema:familyName Davidson
98 schema:givenName Antonia M.
99 rdf:type schema:Person
100 N58fca7773c35404a86a11d45a956ef9f rdf:first sg:person.0746041340.65
101 rdf:rest N3e6c3ee1a422419880b3cae2d2d3767c
102 N5ae1bdcec5eb46aa924a060368519ae8 schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 N5b33d4624f6f4bcfa3ee0b0ae19cbce9 rdf:first N4f23939b8e934c2ab4306a7c5a02b1fd
105 rdf:rest Nb64321fe8a1c4f579705a245eb5e611b
106 N61e0179f02b24062a34b6466bc0826ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Adolescent
108 rdf:type schema:DefinedTerm
109 N6460986bf4a2476b886e48b54956909b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Area Under Curve
111 rdf:type schema:DefinedTerm
112 N69fbb26a16694d2a8fe026d48a05002a rdf:first sg:person.01367544315.00
113 rdf:rest rdf:nil
114 N6a1f63630c01475394e0feafbbb62ef9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Enzyme Induction
116 rdf:type schema:DefinedTerm
117 N76f7179fd5fb4b2bb26fe6aafa1d46de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Adult
119 rdf:type schema:DefinedTerm
120 N7a91b8f5176d4d459ed1648555e6dcfd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Lymphocyte Count
122 rdf:type schema:DefinedTerm
123 N7ebd9338216a480eb78422848da17a6a rdf:first sg:person.0601142577.72
124 rdf:rest N5b33d4624f6f4bcfa3ee0b0ae19cbce9
125 N7ec380c3e725456caa309e1d7a679b67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Biotransformation
127 rdf:type schema:DefinedTerm
128 N882fcd338a9d4b35b899b43e192e9cd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Azetidines
130 rdf:type schema:DefinedTerm
131 N9d81ba9e77ec4328847c82f404a029b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Female
133 rdf:type schema:DefinedTerm
134 N9f62cca8ef33450686a3b58fea9e333a schema:issueNumber 12
135 rdf:type schema:PublicationIssue
136 Na0185dbcc0244a4f93e4812684d8b51b schema:name readcube_id
137 schema:value 407e2069a61a2f88a7fd2c7ae7441fb5601a5f500ea2bbbb43f66f98feb06e3b
138 rdf:type schema:PropertyValue
139 Na36e894bbc5f44458c3304563dfe0c28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Humans
141 rdf:type schema:DefinedTerm
142 Na9e5bd2f36c0482db9526881c4ee8cef rdf:first sg:person.01152111734.09
143 rdf:rest N69fbb26a16694d2a8fe026d48a05002a
144 Nb4fe799a8c814d89867512d5c6c8ca86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Young Adult
146 rdf:type schema:DefinedTerm
147 Nb64321fe8a1c4f579705a245eb5e611b rdf:first sg:person.0716366542.41
148 rdf:rest Na9e5bd2f36c0482db9526881c4ee8cef
149 Nbb843ebfe0db4327a2ae9c49b770ac84 schema:name doi
150 schema:value 10.1007/s00228-018-2533-2
151 rdf:type schema:PropertyValue
152 Nccf2a36f918847198b5beb4a6c21c256 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Healthy Volunteers
154 rdf:type schema:DefinedTerm
155 Nd3fadd97df74497abaf67c461351cba4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Cytochrome P-450 CYP2C9
157 rdf:type schema:DefinedTerm
158 Nd9bb33762ef24b97a38122343e410229 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
159 schema:familyName Gray
160 schema:givenName Cathy
161 rdf:type schema:Person
162 Ne01edeae6cac48ffa5b52f367e2423da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Drug Interactions
164 rdf:type schema:DefinedTerm
165 Nf5ab77fdd6024a61a3f790cb443e439d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Benzyl Compounds
167 rdf:type schema:DefinedTerm
168 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
169 schema:name Medical and Health Sciences
170 rdf:type schema:DefinedTerm
171 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
172 schema:name Clinical Sciences
173 rdf:type schema:DefinedTerm
174 sg:journal.1054337 schema:issn 0031-6970
175 1432-1041
176 schema:name European Journal of Clinical Pharmacology
177 rdf:type schema:Periodical
178 sg:person.01152111734.09 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
179 schema:familyName Legangneux
180 schema:givenName Eric
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152111734.09
182 rdf:type schema:Person
183 sg:person.01254000765.20 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
184 schema:familyName Neelakantham
185 schema:givenName Srikanth
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254000765.20
187 rdf:type schema:Person
188 sg:person.01367544315.00 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
189 schema:familyName Shakeri-Nejad
190 schema:givenName Kasra
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367544315.00
192 rdf:type schema:Person
193 sg:person.0601142577.72 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
194 schema:familyName Huth
195 schema:givenName Felix
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601142577.72
197 rdf:type schema:Person
198 sg:person.0716366542.41 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
199 schema:familyName Dumitras
200 schema:givenName Swati
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716366542.41
202 rdf:type schema:Person
203 sg:person.0746041340.65 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
204 schema:familyName Gardin
205 schema:givenName Anne
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746041340.65
207 rdf:type schema:Person
208 sg:pub.10.1007/s00228-017-2404-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099922651
209 https://doi.org/10.1007/s00228-017-2404-2
210 rdf:type schema:CreativeWork
211 sg:pub.10.1007/s40262-018-0700-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106022094
212 https://doi.org/10.1007/s40262-018-0700-3
213 rdf:type schema:CreativeWork
214 sg:pub.10.1016/j.clpt.2004.08.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033907987
215 https://doi.org/10.1016/j.clpt.2004.08.009
216 rdf:type schema:CreativeWork
217 sg:pub.10.1016/j.clpt.2006.08.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007524447
218 https://doi.org/10.1016/j.clpt.2006.08.002
219 rdf:type schema:CreativeWork
220 sg:pub.10.1186/s12974-016-0686-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042047657
221 https://doi.org/10.1186/s12974-016-0686-4
222 rdf:type schema:CreativeWork
223 sg:pub.10.1208/s12248-012-9367-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031115047
224 https://doi.org/10.1208/s12248-012-9367-0
225 rdf:type schema:CreativeWork
226 sg:pub.10.2165/00003088-200342090-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014227941
227 https://doi.org/10.2165/00003088-200342090-00003
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1016/j.pharmthera.2007.04.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050875697
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1016/s0002-9440(10)64794-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017653173
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1016/s0140-6736(18)30475-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101698897
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1016/s1474-4422(13)70102-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033439649
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1073/pnas.1014154108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013336301
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1093/brain/awq118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041480930
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1093/rheumatology/ker018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022970028
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1111/j.1365-2125.2012.04400.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002553097
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1111/j.1471-4159.2007.04629.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1045180467
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1111/j.1471-4159.2007.4629.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1061939563
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1111/j.1476-5381.2012.02061.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043127544
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1124/dmd.106.010033 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047422604
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1124/dmd.109.027565 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035576216
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1124/dmd.117.079574 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103850020
256 rdf:type schema:CreativeWork
257 https://doi.org/10.2174/157015910792246218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034815003
258 rdf:type schema:CreativeWork
259 https://doi.org/10.2217/pgs.10.49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020935714
260 rdf:type schema:CreativeWork
261 https://doi.org/10.5414/cp202369 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072834516
262 rdf:type schema:CreativeWork
263 https://doi.org/10.5414/cp202588 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072834626
264 rdf:type schema:CreativeWork
265 https://doi.org/10.5414/cp202608 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072834636
266 rdf:type schema:CreativeWork
267 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
268 schema:name Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
269 rdf:type schema:Organization
270 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
271 schema:name Novartis Institutes for BioMedical Research, Basel, Switzerland
272 rdf:type schema:Organization
273 https://www.grid.ac/institutes/grid.423257.5 schema:alternateName Pharmaceutical Product Development (United States)
274 schema:name PPD, Austin, TX, USA
275 rdf:type schema:Organization
276 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
277 schema:name Novartis Healthcare Pvt. Ltd., Hyderabad, India
278 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...